Antiviral drug profile of seasonal influenza viruses circulating in Portugal from 2004/2005 to 2008/2009 winter seasons

Antiviral Research

Volumn 86, Issue 2, 2010, Pages 128-136

  Correia, Vanessa ^a   de Andrade, Helena Rebelo ^a,c   Santos, Luís A ^a   Lackenby, Angie ^b   Zambon, Maria ^b  

^a NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF LISBON   (Portugal)

Author keywords

Amantadine; Antiviral drugs; Influenza; Oseltamivir; Portugal; Resistance

Indexed keywords

AMANTADINE; OSELTAMIVIR; SIALIDASE; ZANAMIVIR;

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; IC 50; INFANT; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MALE; NONHUMAN; PORTUGAL; PRESCRIPTION; PRIORITY JOURNAL; PYROSEQUENCING; WINTER;

ADOLESCENT; ADULT; AGED; AMANTADINE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; OSELTAMIVIR; PORTUGAL; RNA, VIRAL; SEQUENCE ANALYSIS; YOUNG ADULT;

ORTHOMYXOVIRIDAE;

EID: 77951298786     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.01.002     Document Type: Article

References (41)

1. AMC Robust Statistics: A Method of Coping with Outliers. AMC Technical Brief, No. 6 2001, Available on http://www.rsc.org/images/brief6_tcm18-25948.pdf.
2. Aoki F.Y., Boivin G., Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir. Ther. 2007, 12:603-616.
3. Barr I.G., Deng Y.M., Iannello P., Hurt A.C., Komadina N. Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries. Antivir. Res. 2008, 80:200-205.
4. Bliss C.I. Statistics in Biology 1967, vol. 1. McGraw-Hill, New York.
5. Boivin G., Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antivir. Res. 2002, 54:143-147.
6. Boom R., Sol C.J.A., Salimans M.M.M., Jansen C.L., Wertheim-van Dillen P.M., van der Noordaa J. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 1990, 28:495-503.
7. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., Klimov A. Incidence of adamantane resistance among influenza A(H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005, 366:1175-1181.
8. Cheng P.K.C., Leung T.W.C., Ho E.C.M., Leung P.C.K., Ng A.Y.Y., Lai M.Y.Y., Lim W.W.L. Oseltamivir- and amantadine-resistant influenza viruses A(H1N1). Emerg. Infect. Dis. 2009, 15:966-968.
9. Crusat M., de Jong M.D. Neuraminidase inhibitors and their role in avian and pandemic influenza. Antivir. Ther. 2007, 12:593-602.
10. Democratis J., Pareek M., Stephenson I. Use of neuraminidase inhibitors to combat pandemic influenza. J. Antimicrob. Chemother. 2006, 58:911-915.
11. de Jong M.D., Thanh T.T., Khanh T.H., Hien V.M., Smith G.J.D., Chau N.V., Van Cam B., Qui P.T., Ha D.Q., Guan Y., Peiris J.S.M., Hien T.T., Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 2005, 353:2667-2672.
12. Deyde V.M., Xu X., Bright R.A., Shaw M., Smith C.B., Zhang Y., Shu Y., Gubareva L.V., Cox N.J., Klimov A.I. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 2007, 196:249-257.
13. ECDC, 2008. Oseltamivir resistance in seasonal influenza virus. ECDC Online [updated 9.10.08]. Available on http://ecdc.europa.eu/en/Health_Topics/influenza/news/news_Influenza_081009.aspx%23oseltamivir.
14. Ellis J.S., Fleming D.M., Zambon M.C. Multiple reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. J. Clin. Microbiol. 1997, 35:2076-2082.
15. Escuret V., Frobert E., Bouscambert-Duchamp M., Sabatier M., Grog I., Valette M., Lina B., Morfin F., Ferraris O. Detection of human influenza A(H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J. Clin. Virol. 2008, 41:25-28.
16. Ferraris O., Kessler N., Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antivir. Res. 2005, 68:43-48.
17. Hay A.J., Wolstenholme A.J., Skehel J.J., Smith M.H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 1985, 4:3021-3024.
18. Hay A.J., Grambas S., Bennett M.S. Resistance of influenza A viruses to amantadine and rimantadine. Advances in Molecular Biology and Targeted Treatment for AIDS 1991, 343-353. Plenum, New York. A. Kumar (Ed.).
19. Hayden, F.G., 2007. Influenza 1998-2007: antivirals update. Personal communication performed on behalf of WHO Epidemic and Pandemic Alert and Response Department for the Infectious Diseases Society of America. Available on http://www.idsociety.org/.
20. Hurt A.C., Barr I.G., Hartel G., Hampson A.W. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antivir. Res. 2004, 62:37-45.
21. Hurt A.C., Selleck P., Komadina N., Shaw R., Brown L., Barr I.G. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antivir. Res. 2007, 73:228-231.
22. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364:759-765.
23. Lackenby A., Thompson C.I., Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr. Opin. Infect. Dis. 2008, 21:626-638.
24. Lackenby A., Lakhman D., Sadler C., Bedi K., Sebastianpillai P., Baldevarona J., Thompson C., Bennet M., Gregory V., Whittaker L., Hay A., Zambon M. A European surveillance network for influenza antiviral resistance (VIRGIL). Poster presentation. The Third European Influenza Conference 2008.
25. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H.L., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005, 437:1108.
26. McKimm-Breschkin J., Trivedi T., Hampson A., Hay A., Klimov A., Tashiro M., Hayden F.G., Zambon M. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 2003, 47:2264-2272.
27. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 2005, 353:1363-1373.
28. Moscona A. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 2009, 360:953-956.
29. Potier M., Mameli L., Bélisle M., Dallaire L., Melancon S.B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-d-N-acetylneuraminate) substrate. Anal. Biochem. 1979, 94:287-296.
30. Saad M.D., Boynton B.R., Earhart K.C., Mansour M.M., Niman H.L., Elsayed N.M., Nayel A.L., Abdelghani A.S., Essmat H.M., Labib E.M., Ayoub E.A., Monteville M.R. Detection of oseltamivir resistance mutation N294S in humans with influenza A H5N1. Poster presentation. Options for the Control of Influenza VI 2007.
31. Schweiger B., Zadow I., Heckler R., Timm H., Pauli G. Application of a fluorogenic PCR assay for typing and subtyping of influenza viruses in respiratory samples. J. Clin. Microbiol. 2000, 38:1552-1558.
32. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., Butler E., Wallis T.R., Klimov A.I., Gubareva L.V. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 2008, 52:3284-3292.
33. Stouffer A.L., Acharya R., Salom D., Levine A.S., Di Costanzo L., Soto C.S., Tereshko V., Nanda V., Stayrook S., DeGrado W.F. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 2008, 451:596-599.
34. Wang M.Z., Tai C.Y., Mendel D.B. Mechanism by which mutations at His274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob. Agents Chemother. 2002, 46:3809-3816.
35. ®) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 2005, 55(Suppl. 1):i5-i21.
36. Weinstock D.M., Zuccotti G. Adamantane resistance in influenza A. JAMA 2006, 295:934-936.
37. WHO WHO Manual on Animal Influenza Diagnosis and Surveillance. WHO Online 2002, Available on http://www.wpro.who.int/NR/rdonlyres/EFD2B9A7-2265-4AD0-BC98-97937B4FA83C/0/manualonanimalaidiagnosisandsurveillance.pdf.
38. WHO, 2009a. Influenza A virus resistance to oseltamivir and other antiviral medicines. WHO Online [updated 4.06.09]. Available on http://www.who.int/csr/disease/influenza/2008-9nhemisummaryreport/en/index.html.
39. WHO, 2009b. Antiviral drugs and pandemic (H1N1) 2009. WHO Online [updated 6.10.09]. Available on http://www.who.int/csr/disease/swineflu/frequently_asked_questions/swineflu_faq_antivirals/en/index.html.
40. WHO, 2009c. Pandemic (H1N1) 2009-update 71. WHO Online [updated 23.10.09]. Available on http://www.who.int/csr/disease/swineflu/laboratory23_10_2009/en/index.html.
41. WHO, 2009d. Antiviral use and the risk of drug resistance. WHO Online [updated 25.09.09]. Available on http://www.who.int/csr/disease/swineflu/notes/h1n1_antiviral_use_20090925/en/index.html.